

## LITERATURA

1. Hernández JA, Land KJ, McKenna RW. Leukemias, myeloma, and other lymphoreticular neoplasms. *Cancer*. 1995;75:381-394. [https://doi.org/10.1002/1097-0142\(19950101\)75:1<381::AID-CNCR2820751320>3.0.CO;2-B](https://doi.org/10.1002/1097-0142(19950101)75:1<381::AID-CNCR2820751320>3.0.CO;2-B).
2. Smith A, Howell D, Patmore R, et al. Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network. *Br J Cancer*. 2011;105:1684-92. <https://doi.org/10.1038/bjc.2011.450>.
3. Larsson K, Mattsson M, Ebrahim F, et al. High prevalence and incidence of cardiovascular disease in chronic lymphocytic leukaemia: a nationwide population-based study. *Br J Haematol*. 2020;190. <https://doi.org/10.1111/bjh.16859>.
4. Byrd JC, Brown JR, O'Brien S, et al. Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia. *N Engl J Med*. 2014;371:213-223. <https://doi.org/10.1056/NEJMoa1400376>.
5. Ahn IE, Brown JR. Targeting Bruton's Tyrosine Kinase in CLL. *Front Immunol*. 2021;12:687458. <https://doi.org/10.3389/fimmu.2021.687458>.
6. Estupiñán HY, Berglöv A, Zain R, et al. Comparative Analysis of BTK Inhibitors and Mechanisms Underlying Adverse Effects. *Front Cell Dev Biol*. 2021;9:630942. <https://doi.org/10.3389/fcell.2021.630942>.
7. Kaptein A, De Bruin G, Emmelot-van Hoek M, Van De Kar B, De Jong A, Gulrajani M, et al. Potency and Selectivity of BTK Inhibitors in Clinical Development for B-Cell Malignancies. *Blood*. 2018;132:1871-1871. <https://doi.org/10.1182/blood-2018-99-109973>.
8. Smolej L. On the road to optimized BTK inhibition in CLL. *Blood*. 2021;137:3313-4. <https://doi.org/10.1182/blood.2021011462>.
9. Mato AR, Shah NN, Jurczak W, et al. Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study. *The Lancet* 2021;397:892-901. [https://doi.org/10.1016/S0140-6736\(21\)00224-5](https://doi.org/10.1016/S0140-6736(21)00224-5).
10. McMullen JR, Boey EJJ, Ooi JYY, et al. Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling. *Blood*. 2014;124:3829-30. <https://doi.org/10.1182/blood-2014-10-604272>.
11. Weeks KL, Gao X, Du X-J, et al. Phosphoinositide 3-Kinase p110α Is a Master Regulator of Exercise-Induced Cardioprotection and PI3K Gene Therapy Rescues Cardiac Dysfunction. *Circ: Heart Failure*. 2012;5:523-34. <https://doi.org/10.1161/CIRCHEARTFAILURE.112.966622>.
12. Li X, Wang A, Yu K, et al. Discovery of (R)-1-(3-(4-Amino-3-(4-phenoxypheyl)-1-H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)-2-(dimethylamino)ethanone (CHMFL-FLT3-122) as a Potent and Orally Available FLT3 Kinase Inhibitor for FLT3-ITD Positive Acute Myeloid Leukemia. *J Med Chem*. 2015;58:9625-38. <https://doi.org/10.1021/acs.jmedchem.5b01611>.
13. Xiao L, Salem J-E, Claus S, et al. Ibrutinib-Mediated Atrial Fibrillation Attributable to Inhibition of C-Terminal Src Kinase. *Circulation*. 2020;142:2443-2455. <https://doi.org/10.1161/CIRCULATIONAHA.120.049210>.
14. Dickerson T, Wiczter T, Waller A, et al. Hypertension and incident cardiovascular events following ibrutinib initiation. *Blood*. 2019;134:1919-1928. <https://doi.org/10.1182/blood.2019000840>.
15. Ping L, Ding N, Shi Y, et al. The Bruton's tyrosine kinase inhibitor ibrutinib exerts immunomodulatory effects through regulation of tumor-infiltrating macrophages. *Oncotarget*. 2017;8:39218-29. <https://doi.org/10.18632/oncotarget.16836>.
16. Derosa L, Izzedine H, Albages L, et al. Hypertension and angiotensin system inhibitors in patients with metastatic renal cell carcinoma. *Oncol Rev*; 2016. <https://doi.org/10.4081/oncol.2016.298>.
17. Kappers MHW, Van Esch JHM, et al. Hypertension Induced by the Tyrosine Kinase Inhibitor Sunitinib Is Associated With Increased Circulating Endothelin-1 Levels. *Hypertension* 2010;56:675-81. <https://doi.org/10.1161/HYPERTENSION.109.149690>.
18. Rule S, Dreyling M, Goy A, et al. Ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma: extended 3.5-year follow up from a pooled analysis. *Haematologica*. 2019;104:e211-4. <https://doi.org/10.3324/haematol.2018.205229>.
19. Broccoli A, Argnani L, Morigi A, et al. Long-Term Efficacy and Safety of Ibrutinib in the Treatment of CLL Patients: A Real Life Experience. *JCM*. 2021;10:5845. <https://doi.org/10.3390/jcm10245845>.
20. Castillo JJ, Meid K, Gustine JN, et al. Long-term follow-up of ibrutinib monotherapy in treatment-naïve patients with Waldenstrom macroglobulinemia. *Leukemia*. 2022;36:532-539. <https://doi.org/10.1038/s41375-021-01417-9>.
21. Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia. *N Engl J Med*. 2013;369:32-42. <https://doi.org/10.1056/NEJMoa1215637>.
22. Berglöv A, Hamasy A, Meinke S, et al. Targets for Ibrutinib Beyond B Cell Malignancies. *Scand J Immunol*. 2015;82:208-217. <https://doi.org/10.1111/sji.12333>.
23. Tang CPS, McMullen J, Tam C. Cardiac side effects of Bruton tyrosine kinase (BTK) inhibitors. *Leukemia & Lymphoma*. 2018;59:1554-1564. <https://doi.org/10.1080/10428194.2017.1375110>.
24. Ganatra S, Sharma A, Shah S, et al. Ibrutinib-Associated Atrial Fibrillation. *JACC: Clinical Electrophysiology*. 2018;4:1491-500. <https://doi.org/10.1016/j.jacep.2018.06.004>.
25. Lentz R, Feinglass J, Ma S, et al. Risk factors for the development of atrial fibrillation on ibrutinib treatment. *Leukemia & Lymphoma*. 2019;60:1447-1453. <https://doi.org/10.1080/10428194.2018.1533129>.
26. Alexandre J, Moslehi JJ, Bersell KR. Anticancer drug-induced cardiac rhythm disorders: Current knowledge and basic underlying mechanisms. *Pharmacology & Therapeutics*. 2018;189:89-103. <https://doi.org/10.1016/j.pharmthera.2018.04.009>.
27. Joung B. Risk Factor Management for Atrial Fibrillation. *Korean Circ J*. 2019;49:794. <https://doi.org/10.4070/kcj.2019.0212>.
28. Brandes A, Smit MD, Naguey BO, et al. Risk Factor Management in Atrial Fibrillation. *Arrhythmia & Electrophysiology Review*. 2018;7:118. <https://doi.org/10.15420/aer.2018.18.2>.
29. Coutre SE, Furman RR, Flinn IW, et al. Extended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. *Clinical Cancer Research*. 2017;23:1149-1155. <https://doi.org/10.1158/1078-0432.CCR-16-1431>.
30. Chanan-Khan A, Cramer P, Demirkan F, et al. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. *The Lancet Oncology*. 2016;17:200-211. [https://doi.org/10.1016/S1470-2045\(15\)00465-9](https://doi.org/10.1016/S1470-2045(15)00465-9).
31. O'Brien S, Jones JA, Coutre SE, et al. Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study. *The Lancet Oncology*. 2016;17:1409-1418. [https://doi.org/10.1016/S1470-2045\(16\)30212-1](https://doi.org/10.1016/S1470-2045(16)30212-1).
32. Jain P, Keating MJ, Wierda WG, et al. Long-term Follow-up of Treatment with Ibrutinib and Rituximab in Patients with High-Risk Chronic Lymphocytic Leukemia. *Clinical Cancer Research*. 2017;23:2154-8. <https://doi.org/10.1158/1078-0432.CCR-16-1948>.
33. Barr P, Robak T, Owen CJ, et al. Updated Efficacy and Safety from the Phase 3 Resonate-2 Study: Ibrutinib As First-Line Treatment Option in Patients 65 Years and Older with Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia. *Blood*. 2016;128:234-234. <https://doi.org/10.1182/blood.V128.22.234.234>.
34. Farooqui MZH, Valdez J, Martyr S, et al. Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial. *The Lancet Oncology*. 2015;16:169-176. [https://doi.org/10.1016/S1470-2045\(14\)71182-9](https://doi.org/10.1016/S1470-2045(14)71182-9).
35. Byrd JC, Furman RR, Coutre SE, et al. Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib. *Blood*. 2015;125:2497-2506. <https://doi.org/10.1182/blood-2014-10-606038>.
36. Awan FT, Addison D, Alfrahi F, et al. International consensus statement on the management of cardiovascular risk of Bruton's tyrosine kinase inhibitors in CLL. *Blood Advances*. 2022;6:5516-25. <https://doi.org/10.1182/bloodadvances.2022007938>.
37. Onitilo AA, Piwuna TO, Islam N, et al. Determinants of Atrial Fibrillation Development among Patients undergoing Ibrutinib Therapy. *Clin Med Res*. 2022;20:16-22. <https://doi.org/10.3121/cm.2021.1693>.
38. Mato A, Tang B, Azmi S, et al. A real-world study to assess the association of cardiovascular adverse events (CVAEs) with ibrutinib as first-line (1L) treatment for patients with chronic lymphocytic leukaemia (CLL) in the United States. *EJHaem*. 2023;4:135-144. <https://doi.org/10.1002/jha2.638>.
39. Shanafelt TD, Wang XV, Kay NE, et al. Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia. *N Engl J Med*. 2019;381:432-443. <https://doi.org/10.1056/NEJMoa1817073>.
40. Woyach JA, Ruppert AS, Heerema NA, et al. Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL. *N Engl J Med*. 2018;379:2517-2528. <https://doi.org/10.1056/NEJMoa1812836>.
41. Diamond A, Bensken WP, Vu L, et al. Ibrutinib Is Associated With Increased Cardiovascular Events and Major Bleeding in Older CLL Patients. *JACC: CardioOncology*. 2023;5:233-243. <https://doi.org/10.1016/j.jaccao.2023.02.001>.
42. Caldeira D, Alves D, Costa J, et al. Ibrutinib increases the risk of hypertension and atrial fibrillation: Systematic review and meta-analysis. *PLoS ONE*. 2019;14:e0211228. <https://doi.org/10.1371/journal.pone.0211228>.
43. Leong DP, Caron F, Hillis C, et al. The risk of atrial fibrillation with ibrutinib use: a systematic review and meta-analysis. *Blood*. 2016;128:138-140. <https://doi.org/10.1182/blood-2016-05-712828>.
44. Sestier M, Hillis C, Fraser G, et al. Bruton's tyrosine kinase Inhibitors and Cardiotoxicity: More Than Just Atrial Fibrillation. *Curr Oncol Rep*. 2021;23:113. <https://doi.org/10.1007/s11912-021-01102-1>.
45. Heeringa J, Van Der Kuip DAM, Hofman A, et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. *European Heart Journal*. 2006;27:949-53. <https://doi.org/10.1093/eurheartj/ehi825>.
46. Špaček M, Smolej L, Šimkovič M, et al. Idelalisib plus rituximab versus ibrutinib in the treatment of relapsed/refractory chronic lymphocytic leukaemia: A real-world analysis from the Chronic Lymphocytic Leukemia Patients Registry (CLLEAR). *Br J Haematol*. 2023;202:40-47. <https://doi.org/10.1111/bjh.18736>.
47. Bryer E, Itsara A, Ahn IE, et al. Ibrutinib-Associated Sudden Death in Patients with CLL. *Blood*. 2022;140:4133-4134. <https://doi.org/10.1182/blood-2022-160397>.
48. Munir T, Pitchford A, Bloor A, et al. Sudden or Cardiac Deaths on Ibrutinib-Based Therapy Were Associated with a Prior History of Hypertension or Cardiac Disease and the Use of ACE-Inhibitors at Study Entry: Analysis from the Phase III NCRI FLAIR Trial. *Blood*. 2021;138:2636-2636. <https://doi.org/10.1182/blood-2021-152167>.
49. Shanafelt TD, Parikh SA, Noseworthy PA, et al. Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL). *Leukemia & Lymphoma*. 2017;58:1630-9. <https://doi.org/10.1080/10428194.2016.1257795>.

**Další literatura u autora a na [www.onkologics.cz](http://www.onkologics.cz)**